Choose License Type
The demand for live cell encapsulation is predicted to show steady growth in coming years. Increasing public-private funding to finance product development is a key factor accrediting the growth of the live-cell encapsulation industry. In addition, demand development is being fueled by growing research initiatives to assess the therapeutic effectiveness of the cell encapsulation process. Increased outreach campaigns on the role of encapsulation of live cells in the treatment of major chronic diseases such as tumors, autoimmune diseases, etc. is predicted to be the major reason for market movement.
In the therapy of neurological diseases, live-cell encapsulation is a capable technology. Encapsulated drugs have high chances of crossing the blood brain barrier making them readily available therapeutic effect. This technology is antipcated to change the current landscape of treating CNS disorders. Type 1 diabetes is another condition that microencapsulation can treat. The pancreas beta islet cells are killed by the immune system in this state. Encapsulation can protect the drug rom biological environment and make them readily viable for absorption.
For the manufacture of pills, capsules, and intravenous dosage forms for successful delivery systems, cell encapsulation is performed. The growth of this segment involves the growing acceptance of drug delivery cell encapsulation, primarily due to its methodological advantages (such as improved efficacy, reduced toxicity, and improved patient compliance & convenience).
As a drug delivery mechanism, microencapsulation has multiple major benefits. It monitors the release rate of a fused medication specifically over cycles (hours to months), fast administration, pre-programmed drug-release profiles that conform to the patient's clinical requirements. Growing public-private investment and financing for the production of drug delivery services is the key force pushing the business sector.
The aim of the report is to estimate the size of the market for live cell encapsulation and the future growth potential of the market for live cell encapsulation across various segments, such as patient position and component. The base year considered for the analysis is 2019 and from forecast is provided from 2020-2028.
In 2019, North America accounted for the major market of the world market for live cell encapsulation, followed by Europe region with a significant presence. Market growth is attributed to factors such as the involvement of major players, increased per capita spending on healthcare, increased support and investment for research and development projects in the United States and Canada, and the main factors responsible for its significant market share are the existing healthcare system. Furthermore, some of the factors projected to accelerate business growth are favorable government policies and the heavy deployment of digital technologies in the area.
Key vendors in the market include Altucell, Inc, Viacyte, Inc., BÜCHI Labortechnik AG, Sigilon Therapeutics, Inc.,Blacktrace Holdings Ltd,, Evonik Industries,Neurotech Pharmaceuticals, Inc., Living Cell Technologies Ltd.,Gloriana Therapeutics, Kadimastem, Sernova CorporationBeta-O2 Technologies, Inc.,BioTime, Inc. , and Defymed.
Key Segments of the Global Live Cell Encapsulation Market
Manufacturing Technique Overview, 2018-2028 (USD Million)
Polymer Type Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global Live Cell Encapsulation Market
Reasons for the study
What does the report include?
Who should buy this report?
The demand for live cell encapsulation is predicted to show steady growth in coming years. Increasing public-private funding to finance product development is a key factor accrediting the growth of the live-cell encapsulation industry. In addition, demand development is being fueled by growing research initiatives to assess the therapeutic effectiveness of the cell encapsulation process. Increased outreach campaigns on the role of encapsulation of live cells in the treatment of major chronic diseases such as tumors, autoimmune diseases, etc. is predicted to be the major reason for market movement.
In the therapy of neurological diseases, live-cell encapsulation is a capable technology. Encapsulated drugs have high chances of crossing the blood brain barrier making them readily available therapeutic effect. This technology is antipcated to change the current landscape of treating CNS disorders. Type 1 diabetes is another condition that microencapsulation can treat. The pancreas beta islet cells are killed by the immune system in this state. Encapsulation can protect the drug rom biological environment and make them readily viable for absorption.
For the manufacture of pills, capsules, and intravenous dosage forms for successful delivery systems, cell encapsulation is performed. The growth of this segment involves the growing acceptance of drug delivery cell encapsulation, primarily due to its methodological advantages (such as improved efficacy, reduced toxicity, and improved patient compliance & convenience).
As a drug delivery mechanism, microencapsulation has multiple major benefits. It monitors the release rate of a fused medication specifically over cycles (hours to months), fast administration, pre-programmed drug-release profiles that conform to the patient's clinical requirements. Growing public-private investment and financing for the production of drug delivery services is the key force pushing the business sector.
The aim of the report is to estimate the size of the market for live cell encapsulation and the future growth potential of the market for live cell encapsulation across various segments, such as patient position and component. The base year considered for the analysis is 2019 and from forecast is provided from 2020-2028.
In 2019, North America accounted for the major market of the world market for live cell encapsulation, followed by Europe region with a significant presence. Market growth is attributed to factors such as the involvement of major players, increased per capita spending on healthcare, increased support and investment for research and development projects in the United States and Canada, and the main factors responsible for its significant market share are the existing healthcare system. Furthermore, some of the factors projected to accelerate business growth are favorable government policies and the heavy deployment of digital technologies in the area.
Key vendors in the market include Altucell, Inc, Viacyte, Inc., BÜCHI Labortechnik AG, Sigilon Therapeutics, Inc.,Blacktrace Holdings Ltd,, Evonik Industries,Neurotech Pharmaceuticals, Inc., Living Cell Technologies Ltd.,Gloriana Therapeutics, Kadimastem, Sernova CorporationBeta-O2 Technologies, Inc.,BioTime, Inc. , and Defymed.
Key Segments of the Global Live Cell Encapsulation Market
Manufacturing Technique Overview, 2018-2028 (USD Million)
Polymer Type Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global Live Cell Encapsulation Market
Reasons for the study
What does the report include?
Who should buy this report?
1. Introduction
1.1. Introduction to the Study
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Macroeconomic Indicators
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints/Challenges
3.3.3. Opportunities
3.4. Porter’s Five Forces Analysis
3.5. COVID-19 impact analysis
4. Global Live Cell Encapsulation Market by Manufacturing Technique, 2018-2028 (USD Million)
4.1. Liquid Jet Break Up
4.2. Coaxial Airflow
4.3. Simple Dripping
4.4. Electrostatic Dripping
4.5. Vibrating Jet
4.6. Jet Cutting
4.7. Rotating Disk Atomization
5. Global Live Cell Encapsulation Market by Polymer Type , 2018-2028 (USD Million)
5.1. Chitosan
5.2. Siliceous Encapsulates
5.3. Cellulose Sulfate
5.4. Alginate
5.5. HEMA-MMA
5.6. PAN-PVC
5.7. Other Polymers
6. Global Live Cell Encapsulation Market by Application, 2018-2028 (USD Million)
6.1. Drug Delivery
6.2. Regenerative medicine
6.3. Cell Transplantation
6.4. Probiotics
6.5. Research
7. Global Live Cell Encapsulation Market by Region, 2018-2028 (USD Million)
7.1. North America
7.1.1. U.S.
7.1.2. Canada
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Rest of Asia Pacific
7.4. Latin America
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Middle East & Africa
8. Competitive Landscape
8.1. Company Positioning
8.2. Strategic Initiatives
8.2.1. Mergers & Acquisitions
8.2.2. New Product Launch
8.2.3. Investments
8.2.4. Expansion
8.2.5. Others
9. Company Profiles
(Overview, Products and Services Portfolio, Recent Initiatives, Company Financials)
9.1. BioTime, Inc.
9.2. Viacyte, Inc.
9.3. Living Cell Technologies Ltd
9.4. Sigilon Therapeutics, Inc.
9.5. Evonik Industries
9.6. BÜCHI Labortechnik AG
9.7. Blacktrace Holdings Ltd
9.8. Sernova Corporation
9.9. Neurotech Pharmaceuticals, Inc.
9.10. Gloriana Therapeutics
9.11. Kadimastem
9.12. O2 Technologies, Inc.
10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Questionnaire
10.2. Related Reports
10.2.1. Published
10.2.2. Upcoming